Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a new sedative make anesthesia safer for seniors?

NCT ID NCT07746505

Knowledge-focused Sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time

Summary

This study looks at two sedative drugs, remimazolam and midazolam, used to put older adults (65+) to sleep for non-cardiac surgery. The goal is to see which one offers better heart and blood pressure stability, faster recovery, and fewer complications like confusion after surgery. Researchers will observe 1,000 patients without changing their routine care, and use statistical methods to compare the two groups fairly.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
remimazolam and midazolam (two sedative drugs used for general anesthesia)
What this could lead to
If remimazolam proves safer and smoother for older patients, it could become a preferred choice for anesthesia induction, reducing complications like low blood pressure and confusion after surgery.
What could go wrong
This is an observational study, not a controlled experiment, so results may be influenced by other factors. The findings will need confirmation in randomized trials before changing practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Elderly patients (≥65 years) scheduled for elective non-cardiac surgery under general anesthesia at a single tertiary center, who receive a benzodiazepine sedative (remimazolam or midazolam) for induction as part of routine clinical care.

Ages

65 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age 65 years or older. 2. Scheduled for elective non-cardiac surgery under general anesthesia. 3. American Society of Anesthesiologists physical status I to IV. 4. Planned airway management with tracheal intubation or a laryngeal mask airway. 5. Written informed consent provided by the participant or the participant's legally authorized representative. \- Exclusion Criteria: 1. Long-term preoperative benzodiazepine use. 2. Known allergy or contraindication to benzodiazepines, flumazenil, opioids, naloxone, or related drugs. 3. History of drug abuse or alcoholism within the past 2 years. 4. No preoperative cognitive assessment available. 5. Preoperative cognitive impairment, defined as a Mini-Mental State 6.Examination score less than 18. 7.Refusal to provide informed consent. \-

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Aged are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

anxiety anxiety disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Aged Anxiety General anesthesia Intraoperative hypotension

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • The Second Affiliated Hospital of Zhejiang University School of Medicin

    RECRUITING

    Hangzhou, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.